Search Results - Burotto, M.

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial by Choueiri, T.K., Powles, T., Burotto, M., Bourlon, M.T., Zurawski, B., Oyervides Juárez, Víctor Manuel, Hsieh, J.J., Basso, U., Shah, A.Y., Suarez, C., Hamzaj, A., Barrios, C.H., Richardet, M., Pook, D., Tomita, Y., Escudier, B., Zhang, J., Simsek, B., Apolo, A.B., Motzer, R.J.

Get full text